

|                                      |
|--------------------------------------|
| <b>PATENT ASSIGNMENT COVER SHEET</b> |
|--------------------------------------|

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT5876936

|                              |                   |
|------------------------------|-------------------|
| <b>SUBMISSION TYPE:</b>      | NEW ASSIGNMENT    |
| <b>NATURE OF CONVEYANCE:</b> | SECURITY INTEREST |

**CONVEYING PARTY DATA**

| Name                           | Execution Date |
|--------------------------------|----------------|
| CURRAX PHARMACEUTICALS LLC     | 12/13/2019     |
| NALPROPION PHARMACEUTICALS LLC | 12/13/2019     |

**RECEIVING PARTY DATA**

|                        |                                      |
|------------------------|--------------------------------------|
| <b>Name:</b>           | WILMINGTON SAVINGS FUND SOCIETY, FSB |
| <b>Street Address:</b> | 500 DELAWARE AVENUE                  |
| <b>City:</b>           | WILMINGTON                           |
| <b>State/Country:</b>  | DELAWARE                             |
| <b>Postal Code:</b>    | 19801                                |

**PROPERTY NUMBERS Total: 74**

| Property Type  | Number   |
|----------------|----------|
| Patent Number: | 7915307  |
| Patent Number: | 9572814  |
| Patent Number: | 9532971  |
| Patent Number: | 9907780  |
| Patent Number: | 9907779  |
| Patent Number: | 8513299  |
| Patent Number: | 9107898  |
| Patent Number: | 9486437  |
| Patent Number: | 9861607  |
| Patent Number: | 10238620 |
| Patent Number: | 9463181  |
| Patent Number: | 9801847  |
| Patent Number: | 9498462  |
| Patent Number: | 10143676 |
| Patent Number: | 10251859 |
| Patent Number: | 10493053 |
| Patent Number: | 7094429  |
| Patent Number: | 7273623  |
| Patent Number: | 8012506  |

PATENT

| <b>Property Type</b>       | <b>Number</b> |
|----------------------------|---------------|
| <b>Patent Number:</b>      | 8466128       |
| <b>Patent Number:</b>      | 9107882       |
| <b>Patent Number:</b>      | 9937134       |
| <b>Patent Number:</b>      | 7943597       |
| <b>Patent Number:</b>      | 9339481       |
| <b>Patent Number:</b>      | 9610267       |
| <b>Patent Number:</b>      | 9889157       |
| <b>Patent Number:</b>      | 9394318       |
| <b>Patent Number:</b>      | 10150784      |
| <b>Patent Number:</b>      | 8722085       |
| <b>Patent Number:</b>      | 9125868       |
| <b>Patent Number:</b>      | 10307376      |
| <b>Patent Number:</b>      | 8815889       |
| <b>Patent Number:</b>      | 9457005       |
| <b>Patent Number:</b>      | 9633575       |
| <b>Patent Number:</b>      | 10403170      |
| <b>Patent Number:</b>      | 8969371       |
| <b>Patent Number:</b>      | 9119850       |
| <b>Patent Number:</b>      | 9801875       |
| <b>Patent Number:</b>      | 10231964      |
| <b>Patent Number:</b>      | 10231962      |
| <b>Patent Number:</b>      | 9248123       |
| <b>Patent Number:</b>      | 10322121      |
| <b>Patent Number:</b>      | 8916195       |
| <b>Patent Number:</b>      | 9107837       |
| <b>Patent Number:</b>      | 8088786       |
| <b>Patent Number:</b>      | 8318788       |
| <b>Patent Number:</b>      | 7375111       |
| <b>Patent Number:</b>      | 7462626       |
| <b>Patent Number:</b>      | 10238647      |
| <b>Application Number:</b> | 15436293      |
| <b>Application Number:</b> | 15911496      |
| <b>Application Number:</b> | 15911832      |
| <b>Application Number:</b> | 16363128      |
| <b>Application Number:</b> | 16377731      |
| <b>Application Number:</b> | 16699995      |
| <b>Application Number:</b> | 13764467      |
| <b>Application Number:</b> | 14789911      |

| Property Type       | Number   |
|---------------------|----------|
| Application Number: | 13612328 |
| Application Number: | 16686113 |
| Application Number: | 15948598 |
| Application Number: | 13544775 |
| Application Number: | 13991372 |
| Application Number: | 16428069 |
| Application Number: | 15411585 |
| Application Number: | 16534509 |
| Application Number: | 16378177 |
| Application Number: | 16558211 |
| Application Number: | 16356657 |
| Application Number: | 16356663 |
| Application Number: | 16441863 |
| Application Number: | 16284453 |
| Application Number: | 14988556 |
| Application Number: | 15446933 |
| Application Number: | 16363206 |

**CORRESPONDENCE DATA**

**Fax Number:** (212)735-2000

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 212-735-2811

**Email:** mribando@skadden.com

**Correspondent Name:** SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP

**Address Line 1:** FOUR TIMES SQUARE

**Address Line 2:** MONIQUE L. RIBANDO

**Address Line 4:** NEW YORK, NEW YORK 10036

**ATTORNEY DOCKET NUMBER:** 111760/7

**NAME OF SUBMITTER:** OREN EPSTEIN

**SIGNATURE:** /OE/

**DATE SIGNED:** 12/19/2019

**Total Attachments: 11**

source=Currax\_-\_Patent\_Security\_Agreement (Executed)#page1.tif

source=Currax\_-\_Patent\_Security\_Agreement (Executed)#page2.tif

source=Currax\_-\_Patent\_Security\_Agreement (Executed)#page3.tif

source=Currax\_-\_Patent\_Security\_Agreement (Executed)#page4.tif

source=Currax\_-\_Patent\_Security\_Agreement (Executed)#page5.tif

source=Currax\_-\_Patent\_Security\_Agreement (Executed)#page6.tif

source=Currax\_-\_Patent\_Security\_Agreement (Executed)#page7.tif

source=Currax\_-\_Patent\_Security\_Agreement (Executed)#page8.tif

source=Currax\_-\_Patent\_Security\_Agreement (Executed)#page9.tif  
source=Currax\_-\_Patent\_Security\_Agreement (Executed)#page10.tif  
source=Currax\_-\_Patent\_Security\_Agreement (Executed)#page11.tif

## PATENT SECURITY AGREEMENT

THIS PATENT SECURITY AGREEMENT (this "Agreement"), dated as of December 13, 2019, is among Currax Pharmaceuticals LLC, a Delaware limited liability company, and Nalpropion Pharmaceuticals LLC, a Delaware limited liability company (each a "Grantor" and collectively, the "Grantors"), and Wilmington Savings Fund Society, FSB, in its capacity as collateral agent for each member of the Lender Group (as defined in the Credit Agreement referred to below) (in such capacity, together with its successors and assigns in such capacity, "Agent").

### WITNESSETH:

A. Currax Holdings USA LLC, a Delaware limited liability company, as the borrower (the "Borrower") is party to that certain Senior Secured Amended Credit Agreement, dated as of May 31, 2019 (as it may be amended, restated, supplemented, or otherwise modified from time to time, the "Credit Agreement"), by and among the Borrower, Currax Holdings LLC, a Delaware limited liability company ("Parent"), as a Guarantor, the Grantors as Guarantors, the other Guarantors party thereto from time to time, and the Agent and other members of the Lender Group party thereto from time to time, pursuant to which the Lenders have made or from time to time may agree to make Loans and other extensions of credit to the Borrower subject to the terms and conditions set forth in the Credit Agreement.

B. In order to induce the Lender Group to enter into the Credit Agreement, the Grantors entered into (i) that certain Security Agreement, dated as of May 31, 2019 (as it may be amended, restated, supplemented, or otherwise modified from time to time, the "Security Agreement"), made by the Borrower, Parent and the other Grantors in favor of the Agent, (ii) that certain Incremental Agreement and Amendment No. 1, dated as of September 26, 2019, by and among the Borrower, Parent, Currax Pharmaceuticals LLC and the Agent and/or (iii) that certain Assumption Agreement, dated as of September 26, 2019, by Nalpropion Pharmaceuticals LLC in favor of the Agent, as applicable, pursuant to which each Grantor has granted to Agent, for the benefit of the Lender Group, a security interest in and continuing lien on, all of such Grantor's right, title and interest in, to and under all Collateral, including, without limitation, the Patent Collateral (as defined below), in each case whether now owned or existing or hereafter acquired or arising and wherever located to secure the prompt and complete payment and performance in full when due, whether at stated maturity, by required prepayment, acceleration, demand or otherwise, of all Secured Obligations (as defined in the Security Agreement).

C. The Grantors and the Lender Group contemplate and intend that Agent shall have all rights of a secured party in and to the Patent Collateral and any proceeds thereof, including, without limitation, if an Event of Default (as defined in the Credit Agreement) shall occur and be continuing, the right to exercise its remedies under, among other agreements, the Credit Agreement and the Security Agreement and the other Loan Documents (as defined in the Credit Agreement), subject in all respects to the terms and provisions of such agreements, in connection with all of Grantors' right, title and interest in such Patent Collateral.

D. Pursuant to the Credit Agreement, the Security Agreement and the other Loan Documents, the Grantors are required to execute and deliver this Agreement.

**NOW, THEREFORE**, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor agrees as follows:

### **SECTION 1 DEFINED TERMS**

Unless otherwise defined herein, capitalized terms defined in the Security Agreement and used herein have the meaning given to them in the Security Agreement.

## **SECTION 2 GRANT OF SECURITY INTEREST IN PATENTS**

Each Grantor hereby unconditionally grants and pledges and confirms any grant or pledge made pursuant to the Security Agreement, as the case may be, to the Agent, for the ratable benefit of the Lender Group, of a security interest in, and continuing lien on, all of such Grantor's right, title and interest in, to and under the Patents, including but not limited to the registered Patents listed in Schedule A, in each case whether registered or unregistered, now owned or existing or hereafter acquired or arising and wherever located (collectively, the "Patent Collateral"). Notwithstanding anything contained in this Agreement to the contrary, "Patent Collateral" shall not include Excluded Property.

## **SECTION 3 SECURITY FOR OBLIGATIONS**

This Agreement secures, and the Patent Collateral is collateral security for, the prompt and complete payment or performance in full when due of all Secured Obligations.

## **SECTION 4 SECURITY AGREEMENT**

The security interests granted pursuant to this Agreement are granted in conjunction with the security interests granted to the Agent, for the benefit of the Lender Group, pursuant to the Security Agreement and each Grantor hereby acknowledges and affirms that the rights and remedies of the Agent with respect to the security interest in the Patent Collateral made and granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein. In the event of any irreconcilable conflict between the terms of this Agreement and the terms of the Security Agreement, the terms of the Security Agreement shall control.

## **SECTION 5 RECORDATION**

The Grantors hereby authorize and request that the Register of Patents and any other applicable government officer record this Agreement.

## **SECTION 6 MISCELLANEOUS**

This Agreement shall be governed by, and construed in accordance with the laws of the State of New York without regard to its conflict of law principles. THIS AGREEMENT SHALL BE SUBJECT TO THE PROVISIONS REGARDING SUBMISSION TO JURISDICTION AND JURY TRIAL WAIVER SET FORTH IN SECTIONS 8.13 AND 8.15 OF THE SECURITY AGREEMENT, AND SUCH PROVISIONS ARE INCORPORATED HEREIN BY THIS REFERENCE, MUTATIS MUTANDIS.

This Agreement may be executed in counterparts (and by different parties hereto on different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single agreement. Delivery of an executed counterpart of a signature page to this Agreement by facsimile (or other electronic transmission) shall be as effective as delivery of an original executed counterpart of this Agreement.


In entering into this Agreement, and in taking (or refraining from) any actions under or pursuant to this Agreement, the Agent shall be protected by and shall enjoy all of the rights, immunities, protections and indemnities granted to it under the Credit Agreement, the Security Agreement and the other Loan Documents.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]


IN WITNESS WHEREOF, each Grantor has caused this Patent Security Agreement to be duly executed and delivered by its duly authorized officer as of the date first set forth above.

GRANTORS:

CURRAX PHARMACEUTICALS LLC


By:   
Name: Erika Senska  
Title: vice president

NALPROPION PHARMACEUTICALS LLC

By:   
Name: Erika Senska  
Title: vice president

AGENT:

WILMINGTON SAVINGS FUND SOCIETY,  
FSB, as Agent

By:   
Name: **Geoffrey J. Lewis**  
Title: **Vice President**

[Signature Page – Patent Security Agreement]

**PATENT**  
**REEL: 051377 FRAME: 0965**



**SCHEDULE A**

Attached.

**ISSUED PATENTS AND PENDING PATENT APPLICATIONS**

| <b>Patents</b>  |                |                   |                 |                   |
|---|----------------|-------------------|-----------------|-------------------|
| <b>CIRRAX PHARMACEUTICALS, LLC OWNED PATENTS AND PATENT APPLICATIONS</b>      |                |                   |                 |                   |
| <b>Title</b>  | <b>Country</b> | <b>Patent No.</b> | <b>Appl. No</b> | <b>Issue Date</b> |
| Methods of Improving the Pharmacokinetics of Doxepin                          | US             | 7,915,307         | 11/781,165      | 3/29/2011         |
| Methods of Improving the Pharmacokinetics of Doxepin                          | US             | 9,572,814         | 13/653,213      | 2/21/2017         |
| Methods of Improving the Pharmacokinetics of Doxepin                          | US             |                   | 15/436,293      |                   |
| Low-dose Doxepin Formulations and Methods of Making and Using the Same        | US             | 9,532,971         | 13/898,364      | 1/3/2017          |
| Low-dose Doxepin Formulations and Methods of Making and Using the Same        | US             | 9,907,780         | 15/394,912      | 3/6/2018          |
| Low-dose Doxepin Formulations and Methods of Making and Using the Same        | US             |                   | 15/911,496      |                   |
| Ultra-Low Dose Doxepin and Methods of Using the Same to Treat Sleep Disorders | US             | 9,907,779         | 14/045,645      | 3/6/2018          |
| Ultra-Low Dose Doxepin and Methods of Using the Same to Treat Sleep Disorders | US             |                   | 15/911,832      |                   |
| Methods of Using Low-Dose Doxepin for the Improvement of Sleep                | US             | 8,513,299         | 11/804,720      | 8/20/2013         |
| Methods of Using Low-Dose Doxepin for the Improvement of Sleep                | US             | 9,107,898         | 13/492,559      | 8/18/2015         |
| Methods of Using Low-Dose Doxepin for the Improvement of Sleep                | US             | 9,486,437         | 14/804,595      | 11/8/2016         |
| Methods of Using Low-Dose Doxepin for the Improvement of Sleep                | US             | 9,861,607         | 15/344,710      | 1/9/2018          |
| Methods of Using Low-Dose Doxepin for the Improvement of Sleep                | US             | 10,238,620        | 15,864,440      | 3/26/2019         |

|  |    |            |            |  |            |
|--|----|------------|------------|--|------------|
| Improvement of Sleep   |    |            |            |  |            |
| Methods of Using Low-Dose Doxepin for the Improvement of Sleep   | US |            | 16/363,128 |  |            |
| Doxepin Isomers and Isomeric Mixtures and Methods of Using the Same to Treat Sleep Disorders                                   | US | 9,463,181  | 13/692,415 |  | 10/11/2016 |
| Doxepin Isomers and Isomeric Mixtures and Methods of Using the Same to Treat Sleep Disorders                                   | US | 9,801,847  | 15/289,288 |  | 10/31/2017 |
| Doxepin Isomers and Isomeric Mixtures and Methods of Using the Same to Treat Sleep Disorders                                   | US | 9,498,462  | 13/692,715 |  | 11/22/2016 |
| Doxepin Isomers and Isomeric Mixtures and Methods of Using the Same to Treat Sleep Disorders                                   | US | 10,143,676 | 15/357,171 |  | 12/4/2018  |
| Doxepin Isomers and Isomeric Mixtures and Methods of Using the Same to Treat Sleep Disorders                                   | US | 10,251,859 | 15/797,195 |  | 4/9/2019   |
| Doxepin Isomers and Isomeric Mixtures and Methods of Using the Same to Treat Sleep Disorders                                   | US |            | 16/377/731 |  |            |
| Doxepin Isomers and Isomeric Mixtures and Methods of Using the Same to Treat Sleep Disorders                                   | US | 10,493,053 | 16/207,584 |  | 12/03/2019 |
| Doxepin Isomers and Isomeric Mixtures and Methods of Using the Same to Treat Sleep Disorders                                   | US |            | 16/699,995 |  |            |
| Methods of Using Low-Dose Doxepin for the Improvement of Sleep   | US |            | 13/764,467 |  |            |
| Low-Dose Doxepin for Treatment of Sleep Disorders in Elderly Patients  | US |            | 14/789,911 |  |            |
| Combination Therapy Using Low-Dose Doxepin for the Improvement of Sleep  | US |            | 13/612,328 |  |            |
| Low-Dose Doxepin Formulations, Including Buccal, Sublingual and Fast-Melt Formulations, and Uses of the Same to Treat Insomnia | US |            | 16/686,113 |  |            |
| Process for preparing tannate liquid and semi-solid dosage forms   | US | 7,094,429  | 10/921,438 |  | 08/22/2006 |
| Process for preparing tannate tablet, capsule or other   | US | 7,273,623  | 10/269,027 |  | 09/25/2007 |

|  |    |            |            |            |  |
|--|----|------------|------------|------------|--|
| solid dosage forms   |    |            |            |            |  |
| Tannate compositions, methods of making and methods of use                         | US | 8,012,506  | 11/501,649 | 09/06/2011 |  |
| Hyaluronate compositions   | US | 8,466,128  | 12/022,095 | 06/18/2013 |  |
| Hyaluronate compositions   | US | 9,107,882  | 13/915,818 | 08/18/2015 |  |
| Hyaluronate compositions   | US | 9,937,134  | 14/803,841 | 4/10/2018  |  |
| Hyaluronate compositions   | US |            | 15/948,598 |            |  |
| Phosphate-binding chitosan and uses thereof  | US | 7,943,597  | 12/099,433 | 05/17/2011 |  |
| Phosphate-binding chitosan and uses thereof  | US |            | 13/544,775 |            |  |
| Phosphate-binding magnesium salts and uses thereof                                 | US | 9,339,481  | 13/856,084 | 5/17/2016  |  |
| Phosphate-binding magnesium salts and uses thereof                                 | US | 9,610,267  | 15/155,366 | 4/04/2017  |  |
| Phosphate-binding magnesium salts and uses thereof                                 | US | 9,889,157  | 15/477,325 | 2/13/2018  |  |
| Crystal polymorph of magnesium glycinate dihydrate and process for its preparation | US | 9,394,318  | 14/091,070 | 7/19/2016  |  |
| Crystal polymorph of magnesium glycinate dihydrate and process for its preparation | US | 10,150,784 | 15/212,460 | 12/11/2018 |  |

**Patents**

**NALPROPHON PHARMACEUTICALS, INC OWNED PATENTS AND PATENT APPLICATIONS**

| <b>Title</b>  | <b>Country</b> | <b>Patent No.</b> | <b>Appl. No</b> | <b>Issue Date</b> |
|---|----------------|-------------------|-----------------|-------------------|
| Methods For Reducing Binge Or Compulsive Eating             | US             |                   | 13/991372       |                   |
| Methods For Administering Weight Loss Medications           | US             | 8,722,085         | 12/838364       | 5/13/2014         |
| Methods For Administering Weight Loss Medications           | US             | 9,125,868         | 14/220349       | 9/8/2015          |
| Methods For Administering Weight Loss Medications           | US             | 10,307,376        | 16/101853       | 6/4/2019          |
| Methods For Administering Weight Loss Medications           | US             |                   | 16/428069       |                   |
| Compositions And Methods For Reducing Food Cravings         | US             |                   | 15/411585       |                   |
| Increasing Drug Bioavailability In Naltrexone Therapy       | US             |                   | 16/534,509      |                   |
| Compositions And Methods For Increasing Insulin Sensitivity | US             | 8,815,889         | 11/602571       | 8/26/2014         |
| Compositions And Methods For Increasing Insulin Sensitivity | US             | 9,457,005         | 14/326075       | 10/4/2016         |
| Compositions And Methods For Increasing Insulin Sensitivity | US             |                   | 16/378,177      |                   |
| Methods Of Treating Overweight And Obesity                  | US             | 9,633,575         | 14/405775       | 4/25/2017         |
| Methods Of Treating Overweight And Obesity                  | US             | 10,403,170        | 15/491870       | 9/3/2019          |

|  |    |            |           |            |
|--|----|------------|-----------|------------|
| Methods Of Treating Overweight And Obesity                                 | US |            | 16/558211 |            |
| Compositions And Methods For Weight Loss In At Risk Patient Populations    | US | 8,969,371  | 14/322810 | 3/3/2015   |
| Compositions And Methods For Weight Loss In At Risk Patient Populations    | US | 9,119,850  | 14/635518 | 9/1/2015   |
| Compositions And Methods For Weight Loss In At Risk Patient Populations    | US | 9,801,875  | 14/839792 | 10/31/2017 |
| Compositions And Methods For Weight Loss In At Risk Patient Populations    | US | 10,231,964 | 15/725830 | 3/19/2019  |
| Compositions And Methods For Weight Loss In At Risk Patient Populations    | US |            | 16/356657 |            |
| Compositions And Methods For Reducing Major Adverse Cardiovascular Events  | US | 10,231,962 | 15/101878 | 3/19/2019  |
| Compositions And Methods For Reducing Major Adverse Cardiovascular Events  | US |            | 16/356663 |            |
| Methods Of Providing Weight Loss Therapy In Patients With Major Depression | US | 9,248,123  | 12/987909 | 2/2/2016   |
| Methods Of Providing Weight Loss Therapy In Patients With Major Depression | US | 10,322,121 | 15/011120 | 6/18/2019  |

|  |    |            |           |            |
|--|----|------------|-----------|------------|
| Methods Of Providing Weight Loss Therapy In Patients With Major Depression | US |            | 16/441863 |            |
| Sustained Release Formulation Of Naltrexone                                | US | 8,916,195  | 11/757773 | 12/23/2014 |
| Sustained Release Formulation Of Naltrexone                                | US | 9,107,837  | 14/555475 | 8/18/2015  |
| Sustained Release Formulation Of Naltrexone                                | US |            | 16/284453 |            |
| Layered Pharmaceutical Formulations  | US | 8,088,786  | 11/937421 | 1/3/2012   |
| Layered Pharmaceutical Formulations  | US | 8,318,788  | 13/330395 | 11/27/2012 |
| Layered Pharmaceutical Formulations  | US |            | 14/988556 |            |
| Methods For Treating Visceral Fat Conditions                               | US |            | 15/446933 |            |
| Compositions For Affecting Weight Loss                                     | US | 7,375,111  | 10/828795 | 5/20/2008  |
| Compositions For Affecting Weight Loss                                     | US | 7,462,626  | 11/356839 | 12/9/2008  |
| Compositions For Affecting Weight Loss                                     | US | 10,238,647 | 15/276600 | 3/26/2019  |
| Compositions For Affecting Weight Loss                                     | US |            | 16/363206 |            |

PATENT

REEL: 051377 FRAME: 0972